Načítá se...

Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy

The approval of the first two monoclonal antibodies targeting CD38 (daratumumab) and SLAMF7 (elotuzumab) in late 2015 for treating relapsed and refractory multiple myeloma (RRMM) was a critical advance for immunotherapies for multiple myeloma (MM). Importantly, the outcome of patients continues to i...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Front Immunol
Hlavní autoři: Cho, Shih-Feng, Anderson, Kenneth C., Tai, Yu-Tzu
Médium: Artigo
Jazyk:Inglês
Vydáno: Frontiers Media S.A. 2018
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6095983/
https://ncbi.nlm.nih.gov/pubmed/30147690
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2018.01821
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!